Physician prescribing habits can be influenced by samples, continuing medical education sponsorships and conference travel funding, according to a study published in the Journal of the American Medical Association (vol. 283, no. 3).
Physician prescribing habits can be influenced by samples, continuing medical education sponsorships and conference travel funding, according to a study published in the Journal of the American Medical Association (vol. 283, no. 3).
The JAMA report, titled "Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?" analyzed 29 studies found through an article search. Of the articles, 16 addressed the extent of the physician-industry interaction.
According to the study, between 42% and 55% of physicians found samples to be influential as compared to only 22% who said company promotional materials were influential. Only 24% found industry-paid meals to be influential and 12% said lunch rounds and pharmaceutical representative speakers influenced them to prescribe certain medications.
Besides samples, doctors found conference travel (42%) and continuing medical education funding (40%) to be the most influential on their prescribing habits.
The authors cite estimates that the pharmaceutical industry spends more than $11 billion a year in promotion and marketing, $5 billion of which goes to sales representatives. The article also claims that, "It has been estimated that between $8,000 and $13,000 is spent per year on each physician."
An editorial written by Robert M. Tenery, Jr, M.D. in the same issue of the journal concedes that "representatives from the healthcare industry can be a valuable resource for physicians." But, the editorial cautioned that doctors should be wary pharmaceutical representatives' ways. "Physicians should not take as absolute everything they are told by industry representatives," Tenery warned, "and should become cognizant of the potential conflicts created by the increasing level of sophistication in the detailing techniques used by these individuals."
Tenery concluded by saying, "The medical profession and industry must take seriously their obligation to participate in a dialogue that would develop industry-wide standards for the interactions between physicians and healthcare technology industry company representatives." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.